The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Upregulation of cysteinyl leukotriene receptors CysLT1 and CysLT2 by TGF-β1 and LTE4 on human bronchial epithelial cells Source: Annual Congress 2006 - Airway epithelial cells in inflammation Year: 2006
Expression of the cysteinyl leukotriene receptors cysLT1 and cysLT2 in the airway structural cells Source: Eur Respir J 2005; 26: Suppl. 49, 346s Year: 2005
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 20s Year: 2004
The Cys-LT1 receptor antagonist, pranlukast, attenuates allergen-induced increase in airway eosinophils and bone marrow derived eosinophil/basophil progenitors in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 349s Year: 2003
A leukotriene antagonist, montelukast, reduces in vitro LTD4 increases in peripheral blood eosinophil progenitor colonies in atopic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 531s Year: 2001
The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003
Effect of cysteinyl leukotriene receptor antagonist on airway wall remodeling Source: Eur Respir J 2002; 20: Suppl. 38, 304s Year: 2002
Effects of a newly developed dual CysLT1 and CysLT2 receptor antagonist, ONO-RS-531, on antigen- and leukotriene D4 -induced contractions of isolated human bronchi Source: Eur Respir J 2005; 26: Suppl. 49, 214s Year: 2005
SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia in healthy subjects Source: Annual Congress 2007 - New drugs for COPD Year: 2007
Leukotriene B4 receptor blockade increases apoptosis of monocyte-derived macrophages from patients with COPD and emphysema Source: Eur Respir J 2001; 18: Suppl. 33, 337s Year: 2001
Effects of leukotriene receptor antagonists on airway mucus secretion Source: Eur Respir J 2001; 18: Suppl. 33, 245s Year: 2001
Comparison of glucocorticoid and cysteinyl leukotriene receptor antagonist treatments in the airway remodeling induced by chronic airway inflammation in guinea pigs Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 Source: Eur Respir J 2013; 41: 46-52 Year: 2013
Anti-inflammatory effects of histamine H1 -receptor antagonist and leukotriene CysLT1 -receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
Alternative transcripts of cysteinyl leukotriene receptor 1 in patients with bronchial asthma Source: Annual Congress 2007 - Novel mediators of cellular pathology Year: 2007